UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.2

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Introduction

On June 2, 2025, atai entered into a Share Purchase Agreement (the “Share Purchase Agreement”) with ▇▇▇▇▇▇▇ Psytech and certain selling shareholders of ▇▇▇▇▇▇▇ Psytech, pursuant to which atai agreed to acquire from the shareholders of ▇▇▇▇▇▇▇ Psytech, excluding atai (the “Sellers”) the entire issued share capital of ▇▇▇▇▇▇▇ Psytech not already owned by atai (“▇▇▇▇▇▇▇ Shares”) by issuing to the Sellers 105,044,902 Ordinary Shares (the “Consideration Shares”). Prior to the Closing, ▇▇▇▇▇▇▇ Psytech will use all reasonable endeavors to effect the ▇▇▇▇▇▇▇ Carve-Out, pursuant to which Eleusis and its subsidiaries (“Eleusis”) will be carved out from ▇▇▇▇▇▇▇ Psytech by way of a dividend in specie of all of the issued shares in Eleusis such that the shareholders of ▇▇▇▇▇▇▇ Psytech immediately prior to the ▇▇▇▇▇▇▇ Carve-Out shall each receive a pro-rata equity holding in Eleusis (see Note 3). The Closing is expected to be completed in the second half of 2025. Upon completion of the Acquisition, ▇▇▇▇▇▇▇ Psytech and its subsidiaries (“▇▇▇▇▇▇▇ Group”) will be wholly-owned subsidiaries of atai. Upon the completion of the Acquisition, the Combined Group will be renamed to “▇▇▇▇ ▇▇▇▇▇▇▇ N.V.”

Subsequent to the execution of the Share Purchase Agreement, on July 1, 2025, atai entered into subscription agreements relating to the purchase of (i) 18,264,840 Ordinary Shares and (ii) pre-funded warrants (the “July Pre-Funded Warrants”) to purchase 4,566,210 Ordinary Shares with an exercise price of $0.01, for a purchase price of $2.19 per share less the exercise price of $0.01 per share, resulting in aggregate gross proceeds to atai of approximately $50.0 million (the “July PIPE Financing”).

Additionally, on August 13, 2025 atai and ▇▇▇▇▇▇▇ Psytech entered into a senior promissory note (the “Promissory Note”), pursuant to which atai will advance an aggregate principal amount of up to $10.0 million to ▇▇▇▇▇▇▇ Psytech to be used for the achievement of certain development milestones of BPL-003 (see Note 1, Promissory Note).

Furthermore, atai is expected to effect the Redomiciliation, pursuant to which (i) atai will merge with and into atai LuxCo (the “LuxCo Merger”), a newly formed Luxembourg public limited liability company (société anonyme), with atai LuxCo surviving, and all Ordinary Shares will be cancelled and exchanged for atai LuxCo Common Stock on a one-for-one basis; and (ii) atai LuxCo will subsequently convert from a Luxembourg public limited liability company (société anonyme) into atai Delaware, a corporation incorporated under the laws of the State of Delaware, and atai LuxCo will be deregistered from the Luxembourg Register of Commerce and Companies (Registre de Commerce et des Sociétés). The Redomiciliation is expected to be completed before the end of 2025 prior to the Acquisition. See “The Redomiciliation” for further details on the background and reasons for the Redomiciliation. As this is a one-for-one exchange of shares with the same par value, atai does not expect the Redomiciliation to have a material effect on its consolidated financial statements. The Redomiciliation is not expected to have a material effect on atai’s effective tax rate. In connection with the Redomiciliation, atai estimates the related transaction costs to be approximately $3.0 million, with the corresponding effect recognized in the unaudited pro forma condensed combined financial information.

Any atai shareholders who vote against the Redomiciliation and who do not wish to receive atai LuxCo Common Stock may exercise their withdrawal rights under Dutch law in connection with the LuxCo Merger and receive cash compensation up to a maximum of $5.0 million in aggregate (see “Conditions to the Redomiciliation”). If the maximum cash compensation under such withdrawal rights is reached, then the pro forma combined balance of cash and cash equivalents will be reduced by $5.0 million and the outstanding shares of the Combined Group will be reduced by 1,106,194 shares using the closing trading price of atai Ordinary Shares on September 3, 2025. As a result, basic and diluted pro forma net loss per share would be $0.28 for the six months ended June 30, 2025 and $2.56 for the year ended December 31, 2024.

The unaudited pro forma condensed combined financial information has been prepared by atai in accordance with Regulation S-X Article 11, Pro Forma Financial Information, as amended by the final rule, Amendments to Financial Disclosures About Acquired and Disposed Business, as adopted by the SEC on May 20, 2020 (“Article 11”). The following unaudited pro forma condensed combined financial information gives effect to the Acquisition, the July PIPE Financing, the ▇▇▇▇▇▇▇ Carve-Out, the Redomiciliation, the Promissory Note, and other related transactions.

1
The unaudited pro forma condensed combined balance sheet combines the historical consolidated balance sheet of atai and the historical consolidated statement of financial position of ▇▇▇▇▇▇▇ Psytech, as adjusted for the ▇▇▇▇▇▇▇ Carve-Out (“Adjusted ▇▇▇▇▇▇▇ Psytech”) described in Note 3, as of June 30, 2025, and depicts the accounting for the Acquisition, the July PIPE Financing (presented as “July PIPE Financing” adjustments), the Redomiciliation, the Promissory Note, and related transactions (“pro forma balance sheet transaction accounting adjustments”). The unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2025 and for the year ended December 31, 2024 combines the historical consolidated results of atai and the historical consolidated statement of comprehensive loss of ▇▇▇▇▇▇▇ Psytech, as adjusted for ▇▇▇▇▇▇▇ Carve-Out described in Note 3 for those periods and depicts the pro forma balance sheet transaction accounting adjustments for the Acquisition, the July PIPE Financing (presented as “July PIPE Financing” adjustments), the Redomiciliation, the Promissory Note, and related transactions assuming that those adjustments were made as of January 1, 2024 (“pro forma statements of operations transaction accounting adjustments”). Collectively, pro forma balance sheet transaction accounting adjustments and pro forma statements of operations transaction accounting adjustments are referred to as “transaction accounting adjustments.” These unaudited pro forma condensed combined financial information and related notes have been derived from and should be read in conjunction with:


 •
the historical audited consolidated financial statements of atai for the year ended December 31, 2024, and the related notes, and Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in its Annual Report on Form 10-K, filed with the SEC on March 17, 2025 and incorporated by reference;


•
the historical unaudited condensed consolidated financial statements of atai for the six months ended June 30, 2025, and the related notes, and Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in its Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025 and incorporated by reference;


•
the historical consolidated financial statements of ▇▇▇▇▇▇▇ Psytech for the year ended December 31, 2024 filed herewith as Exhibit 99.1 to atai’s Current Report on Form 8-K, filed with the SEC on September 29, 2025;

▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇’s unaudited historical interim condensed consolidated financial statements for the six months ended and as of June 30, 2025 are not included herein .

The transaction accounting adjustments to the unaudited pro forma condensed combined financial information is based on the assumptions described in the accompanying notes. The unaudited pro forma condensed combined financial information is not necessarily indicative of the financial position or results of operations in the future periods or the result that actually would have been realized had atai and ▇▇▇▇▇▇▇ Psytech been a combined organization during the specified periods.

2
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

AS OF JUNE 30, 2025
(in thousands of dollars)

   
Historical
                                            
   
atai
(U.S. GAAP)
    
▇▇▇▇▇▇▇
Psytech
(IFRS)
(Note 2)
    
▇▇▇▇▇▇▇
Carve-Out
(Note 3)
        
Adjusted
▇▇▇▇▇▇▇
Psytech
    
July
PIPE
Financing
(Note 4)
        
Transaction
Accounting
Adjustments
        
Pro Forma
Combined
  
Assets
                                                      
Current assets:
                                                      
Cash and cash equivalents
  
$
61,940
    
$
2,228
    
$
(58
)
  
3(a)
  
$
2,170
    
$
46,663
    
4(a)
  
$
4,542
    
8(a)
  
$
103,660
  
 
                                                    
(11,655
)
  
8(c)
        
 
                                                    
(10,000
)
  
8(b)
        
 
                                                    
10,000
    
8(d)
        
Securities carried at fair value
    
34,003
      
—
      
—
          
—
      
—
          
—
          
34,003
  
Other receivables
    
—
      
1,463
      
(232
)
  
3(a)
    
1,231
      
—
          
(1,231
)
  
8(e.2)
    
—
  
Note receivable from ▇▇▇▇▇▇▇ Psytech
    
—
      
—
      
—
          
—
      
—
          
10,000
    
8(b)
    
—
  
 
                                                    
(10,000
)
  
8(g)
        
Tax receivables
    
—
      
11,958
      
(1,912
)
  
3(a)
    
10,046
      
—
          
—
          
10,046
  
Prepaid expenses and other current assets
    
6,738
      
—
      
—
          
—
      
—
          
1,231
    
8(e.2)
    
7,969
  
Total current assets
    
102,681
      
15,649
      
(2,202
)
        
13,447
      
46,663
          
(7,113
)
        
155,678
  
Property and equipment, net
    
2,899
      
—
      
—
          
—
      
—
          
—
          
2,899
  
Property, plant and equipment
    
—
      
103
      
(87
)
  
3(a)
    
16
      
—
          
(16
)
  
8(g)
    
—
  
Operating lease right-of-use asset, net
    
2,803
      
—
      
—
          
—
      
—
          
—
          
2,803
  
Other investments held at fair value
    
16,816
      
—
      
—
          
—
      
—
          
—
          
16,816
  
Other investments
    
53,947
      
—
      
—
          
—
      
—
          
(45,418
)
  
8(g)
    
1,800
  
 
                                                    
1,800
    
8(g)
        
 
                                                    
(8,529
)
  
8(g)
        
Intangible assets
    
3,122
      
66,594
      
(66,594
)
  
3(a)
    
—
      
—
          
536,000
    
8(g)
    
3,122
  
 
                                                    
(536,000
)
  
8(h)
        
Goodwill
    
331
      
—
      
—
          
—
      
—
          
—
          
331
  
Digital assets
    
6,216
      
—
      
—
          
—
      
—
          
—
          
6,216
  
Other receivables
    
—
      
3,142
      
(3,142
)
  
3(a)
    
—
      
—
          
—
          
—
  
Other assets
    
389
      
—
      
—
          
—
      
—
          
—
          
389
  
Total assets
  
$
189,204
    
$
85,488
    
$
(72,025
)
      
$
13,463
    
$
46,663
        
$
(59,276
)
      
$
190,054
  
                                                                     
Liabilities and stockholders’ equity
                                                                    
Current liabilities:
                                                                    
Accounts payable
  
$
4,039
    
$
—
    
$
—
        
$
—
    
$
—
        
$
(210
)
  
8(c)
  
$
6,346
  
                                                     
2,517
    
8(e.2)
        
Trade and other payables
    
—
      
4,956
      
(84
)
  
3(a)
    
4,872
      
—
          
(4,872
)
  
8(e.2)
    
—
  
Accrued liabilities
    
14,514
      
—
      
—
          
—
      
—
          
(3,218
)
  
8(c)
    
15,904
 
                                                     
2,355
    
8(e.2)
        
                                                      2,253
    8(i)
       
Note payable to atai
    
—
      
—
      
—
          
—
      
—
          
10,000
    
8(d)
    
—
  
                                                     
(10,000
)
  
8(g)
        

See accompanying notes to the unaudited pro forma condensed combined financial information.

3

   
Historical
                                            
   
atai
(U.S. GAAP)
    
▇▇▇▇▇▇▇
Psytech
(IFRS)
(Note 2)
    
▇▇▇▇▇▇▇
Carve-Out
(Note 3)
        
Adjusted
▇▇▇▇▇▇▇
Psytech
    
July
PIPE
Financing
(Note 4)
        
Transaction
Accounting
Adjustments
        
Pro Forma
Combined
  
Current portion of lease liabilities
    
437
      
—
      
—
          
—
      
—
          
—
          
437
  
Short-term convertible promissory notes and derivative liability - related party
    
2,466
      
—
      
—
          
—
      
—
          
—
          
2,466
  
Short-term convertible promissory notes and derivative liability
    
3,694
      
—
      
—
          
—
      
—
          
—
          
3,694
  
Contingent consideration
    
—
      
18,177
      
—
          
18,177
      
—
          
—
          
18,177
  
Other current liabilities
    
397
      
—
      
—
          
—
      
—
          
—
          
397
  
Total current liabilities
    
25,547
      
23,133
      
(84
)
        
23,049
      
—
          
( 1,175
)
        
47,421
 
Contingent consideration liability - related parties
    
110
      
—
      
—
          
—
      
—
          
—
          
110
  
Contingent consideration liabilities
    
212
      
8,205
      
—
          
8,205
      
—
          
—
          
8,417
  
Noncurrent portion of lease liabilities
    
2,619
      
—
      
—
          
—
      
—
          
—
          
2,619
  
Warrants
    
—
      
437
      
—
          
437
      
—
          
(437
)
  
8(f)
    
—
  
Pre-funded warrant liabilities
    
13,758
      
—
      
—
          
—
      
9,954
    
4(a)
    
—
          
23,712
  
Other liabilities
    
3,033
      
—
      
—
          
—
      
—
          
—
          
3,033
  
Total liabilities
    
45,279
      
31,775
      
(84
)
        
31,691
      
9,954
          
( 1,612
)
        
85,312
 
Stockholders’ equity:
                                                                    
atai common stock
    
23,547
      
—
      
—
          
—
      
2,141
    
4(a)
    
350
    
8(a)
    
37,933
  
 
                    
—
                              
11,895
    
8(g)
        
Share capital
    
—
      
14
      
—
          
14
      
—
          
(14
)
  
8(g)
    
—
  
Share premium
    
—
      
131,402
      
(71,191
)
  
3(a)
    
60,211
      
—
          
(60,211
)
  
8(g)
    
—
  
Merger reserve
    
—
      
43,942
      
—
          
43,942
      
—
          
(43,942
)
  
8(g)
    
—
  
Additional paid-in capital
    
895,486
      
—
      
—
          
—
      
35,226
    
4(a)
    
4,192
    
8(a)
    
1,382,310
  
 
                                                    
(1,678
)
  
8(e.1)
        
 
                                                    
1,678
    
8(g)
        
 
                                                    
446,888
    
8(g)
        
 
                                                    
518
    
8(g)
        
Accumulated other comprehensive loss
    
(20,928
)
    
—
      
—
          
—
      
—
          
—
          
(20,928
)
Cumulative translation adjustment
    
—
      
(772
)
    
(750
)
  
3(a)
    
(1,522
)
    
—
          
1,522
    
8(g)
    
—
  
Accumulated deficit
    
(754,367
)
    
(120,873
)
    
—
          
(120,873
)
    
(658
)
  
4(a)
    
(8,227
)
  
8(c)
    
( 1,294,760
)
                                                     
1,678
    
8(e.1)
        
                                                     
437
    
8(f)
        
                                                     
118,758
    
8(g)
        
                                                     
6,745
    
8(g)
        
                                                     
(536,000
)
  
8(h)
        
                                                      (2,253
)   8(i)
       

See accompanying notes to the unaudited pro forma condensed combined financial information.

4

   
Historical
                                            
   
atai
(U.S. GAAP)
    
▇▇▇▇▇▇▇
Psytech
(IFRS)
(Note 2)
    
▇▇▇▇▇▇▇
Carve-Out
(Note 3)
        
Adjusted
▇▇▇▇▇▇▇
Psytech
    
July
PIPE
Financing
(Note 4)
        
Transaction
Accounting
Adjustments
        
Pro Forma
Combined
  
Total stockholders’ equity attributable to atai Life Sciences N.V. stockholders and ▇▇▇▇▇▇▇ Psytech Limited shareholders
    
143,738
      
53,713
      
(71,941
)
        
(18,228
)
    
36,709
          
(57,664
)
       
104,555
  
Noncontrolling interests
    
187
      
—
      
—
          
—
      
—
          
—
          
187
  
Total stockholders’ equity
    
143,925
      
53,713
      
(71,941
)
        
(18,228
)
    
36,709
          
( 57,664
)
        
104,742
 
Total liabilities and stockholders’ equity
  
$
189,204
    
$
85,488
    
$
(72,025
)
      
$
13,463
    
$
46,663
        
$
(59,276
)
      
$
190,054
  

See accompanying notes to the unaudited pro forma condensed combined financial information.

5
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

FOR THE SIX MONTHS ENDED JUNE 30, 2025
(in thousands of dollars, except shares and per share amounts)

   
Historical
                                          
   
Atai
(U.S. GAAP)
    
▇▇▇▇▇▇▇
Psytech
(IFRS)
(Note 2)
    
▇▇▇▇▇▇▇
Carve-Out
(Note 3)
        
Adjusted
▇▇▇▇▇▇▇
Psytech
    
Transaction
Accounting
Adjustments
        
Pro Forma
Combined
    
License revenue
  
$
202
    
$
—
    
$
—
        
$
—
    
$
—
        
$
202
    
Research and development services revenue
    
2,072
      
—
      
—
          
—
      
—
          
2,072
    
Total revenue
    
2,274
      
—
      
—
          
—
      
—
          
2,274
    
Operating expenses:
                                                                  
Research and development
    
22,420
      
14,907
      
(1,233
)
  
3(b)
    
13,674
      
282
    
9(d)
    
36,376
    
General and administrative
    
25,497
      
6,821
      
(296
)
  
3(b)
    
6,525
      
193
    
9(d)
    
32,215
    
Loss on contingent consideration
    
—
      
18,456
      
—
          
18,456
      
—
          
18,456
    
Total operating expenses
    
47,917
      
40,184
      
(1,529
)
        
38,655
      
475
          
87,047
    
Loss from operations
    
(45,643
)
    
(40,184
)
    
1,529
          
(38,655
)
    
(475
)
        
(84,773
)
  
Other income (expense), net:
                                                                  
Interest income
    
434
      
99
      
—
          
99
                  
533
    
Interest expense
    
(1,164
)
    
(110
)
    
—
          
(110
)
    
—
          
(1,274
)
  
Gain on revaluation of warrants
    
—
      
8,842
      
—
          
8,842
      
(8,842
)
  
9(b)
    
—
    
Benefit from research and development tax credit
    
56
      
—
      
—
          
—
      
—
          
56
    
Change in fair value of assets and liabilities, net
    
(12,502
)
    
—
      
—
          
—
      
2,783
    
9(a)
    
(9,719
)
  
Gain on other investments
    
3,794
      
—
      
—
          
—
      
—
          
3,794
    
Change in fair value of digital assets, net
    
1,216
      
—
      
—
          
—
      
—
          
1,216
    
Loss on extinguishment of debt
    
(1,317
)
    
—
      
—
          
—
      
—
          
(1,317
)
  
Foreign exchange gain, net
    
1,916
      
—
      
—
          
—
      
—
          
1,916
    
Other expense, net
    
(752
)
    
—
      
—
          
—
      
—
          
(752
)
  
Net income (loss) before income taxes
    
(53,962
)
    
(31,353
)
    
1,529
          
(29,824
)
    
(6,534
)
        
(90,320
)
  
Benefit from (provision for) income taxes
    
(249
)
    
5,093
      
(200
)
  
3(b)
    
4,893
      
—
          
4,644
    
Net loss
    
(54,211
)
    
(26,260
)
    
1,329
          
(24,931
)
    
(6,534
)
        
(85,676
)
  
Net loss attributable to noncontrolling interests
    
(51
)
    
—
      
—
          
—
      
—
          
(51
)
  
Net loss attributable to common stockholders
  
$
(54,160
)
  
$
(26,260
)
  
$
1,329
        
$
(24,931
)
  
$
(6,534
)
      
$
(85,625
)
  
Net loss per share attributable to common stockholders — basic and diluted
  
$
(0.29
)
                                          
$
(0.28
)
9( h )
Weighted average common shares outstanding — basic and diluted
    
186,473,494
                                              
309,226,088
  
9( h )

See accompanying notes to the unaudited pro forma condensed combined financial information.

6
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

FOR THE YEAR ENDED DECEMBER 31, 2024
(in thousands of dollars, except shares and per share amounts)

   
Historical
                                                      
   
atai
(GAAP)
    
▇▇▇▇▇▇▇
Psytech
(IFRS)
(Note 2)
    
▇▇▇▇▇▇▇
Carve-Out
(Note 3)
        
Adjusted
▇▇▇▇▇▇▇
Psytech
    
July
PIPE
Financing
(Note 4)
        
Transaction
Accounting
Adjustments
        
Pro Forma
Combined
    
License revenue
  
$
308
    
$
—
    
$
—
        
$
—
    
$
—
        
$
—
        
$
308
    
Operating expenses:
                                                                                
Research and development
    
55,455
      
31,237
      
(4,685
)
  
3(b)
    
26,552
      
—
          
696
    
9(d)
    
82,703
    
General and administrative
    
47,544
      
10,202
      
(1,215
)
  
3(b)
    
8,987
      
658
    
4(b)
    
145
    
9(d)
    
67,814
   
                                                     
8,227
    
9(c)
           
                                                      2,253
    9(g)
         
Loss on contingent consideration
    
—
      
4,465
      
—
          
4,465
      
—
          
—
          
4,465
    
Total operating expenses
    
102,999
      
45,904
      
(5,900
)
        
40,004
      
658
          
11,321
         
154,982
   
Loss from operations
    
(102,691
)
    
(45,904
)
    
5,900
          
(40,004
)
    
(658
)
        
( 11,321
)
        
( 154,674
)
  
Other income (expense), net:
                                                                                
Interest income
    
778
      
1,187
      
—
          
1,187
      
—
          
—
          
1,965
    
Interest expense
    
(3,124
)
    
—
      
—
          
—
      
—
          
—
          
(3,124
)
  
Acquired in-process research and development
    
—
      
—
      
—
          
—
      
—
          
(536,000
)
  
9(f)
    
(536,000
)
  
Gain on Acquisition
    
—
      
—
      
—
          
—
      
—
          
6,745
    
9(e)
    
6,745
    
Gain on revaluation of warrants
    
—
      
5,291
      
—
          
5,291
      
—
          
(5,291
)
  
9(b)
    
—
    
Benefit from research and development tax credit
    
525
      
—
      
—
          
—
      
—
          
—
          
525
    
Change in fair value of assets and liabilities, net
    
(48,879
)
    
—
      
—
          
—
      
—
          
(1,676
)
  
9(a)
    
(50,555
)
  
Gain on settlement of pre-existing contract
    
5,567
      
—
      
—
          
—
      
—
          
—
          
5,567
    
Gain on dissolution of a variable interest entity
    
1,166
      
—
      
—
          
—
      
—
          
—
          
1,166
    
Foreign exchange loss, net
    
(1,263
)
    
—
      
—
          
—
      
—
          
—
          
(1,263
)
  
Other expense, net
    
(484
)
    
—
      
—
          
—
      
—
          
—
          
(484
)
  
Net income (loss) before income taxes
    
(148,405
)
    
(39,426
)
    
5,900
          
(33,526
)
    
(658
)
        
( 547,543
)
        
( 730,132
)
  
Benefit from (provision for) income taxes
    
356
      
10,713
      
(903
)
  
3(b)
    
9,810
      
—
          
—
          
10,166
    
Losses from investments in equity method investees, net of tax
    
(2,000
)
    
—
      
—
          
—
      
—
          
—
          
(2,000
)
  
Net loss
    
(150,049
)
    
(28,713
)
    
4,997
          
(23,716
)
    
(658
)
        
( 547,543
)
        
( 721,966
)
  
Net loss attributable to noncontrolling interests
    
(780
)
    
—
      
—
          
—
      
—
          
—
          
(780
)
  
Net loss attributable to common stockholders
  
$
(149,269
)
  
$
(28,713
)
  
$
4,997
        
$
(23,716
)
  
$
(658
)
      
$
( 547,543
)
      
$
( 721,186
)
  
Net loss per share attributable to common stockholders — basic and diluted
  
$
(0.93
)
                                                      
$
( 2.55
)
9( h )
Weighted average common shares outstanding — basic and diluted
    
160,159,983
                                                          
282,912,577
  
9( h )

See accompanying notes to the unaudited pro forma condensed combined financial information.

7
NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

1. Description of the Acquisition

On June 2, 2025, atai, the Sellers and ▇▇▇▇▇▇▇ Psytech entered into the Share Purchase Agreement, pursuant to which atai agreed to acquire the ▇▇▇▇▇▇▇ Shares from the Sellers. Prior to entering into the Share Purchase Agreement, on January 3, 2024 atai (i) entered into a subscription and shareholders’ agreement (the “SSA”) with ▇▇▇▇▇▇▇ Psytech, pursuant to which atai acquired 24,096,385 newly issued series C preferred shares of ▇▇▇▇▇▇▇ Psytech, nominal value £0.0001 per share (the “Series C Shares”), and (ii) received an equity warrant instrument, pursuant to which atai acquired 24,096,385 warrants to purchase an amount of Series C Shares, as well as additional warrants to be issued to atai in the event that ▇▇▇▇▇▇▇ Psytech issues equity or equity linked securities pursuant to a deferred equity arrangement in connection with a prior acquisition made by ▇▇▇▇▇▇▇ Psytech. See below under “Pre-Existing Investment in ▇▇▇▇▇▇▇ Psytech.” As of June 30, 2025, atai holds a 33.7% investment in ▇▇▇▇▇▇▇ Psytech.

Upon Closing, the following will be effected:


 •
The entire issued share capital of ▇▇▇▇▇▇▇ Psytech, other than the shares already held by atai, will be exchanged for 105,044,902 Consideration Shares (see Note 7).


•
All options of the ordinary shares in ▇▇▇▇▇▇▇ Psytech (the “▇▇▇▇▇▇▇ Options”) shall be cancelled at Closing. At atai’s sole discretion, certain holders of ▇▇▇▇▇▇▇ Options that are fully vested and deemed to be “in the money” at Closing (the “Vested and In-the-money ▇▇▇▇▇▇▇ Options”) will either receive (i) replacement awards in atai restricted stock units or atai stock options (the “Replacement Awards”) (which shall be fully vested and immediately exercisable, subject to the below lock-up provisions), (ii) Consideration Shares, or (iii) a combination of the foregoing. ▇▇▇▇▇▇▇ Options held by any ▇▇▇▇▇▇▇ Optionholder who is a former employee or former contractor of ▇▇▇▇▇▇▇, or a non-natural person, shall lapse at Closing unless exercised (and the exercise price and related taxes paid) prior to Closing. See below under “Replacement Awards and Consideration Shares.”


•
Subsequent to the Closing, any ▇▇▇▇▇▇▇ Options that are unvested and/or underwater at Closing shall be replaced with an award of equivalent value of atai’s stock pursuant to atai’s incentive plan which shall not reduce or otherwise change the aggregate number of Consideration Shares issued to the Sellers.


•
Prior to the Closing, atai and the Sellers will use all reasonable endeavors to effect the ▇▇▇▇▇▇▇ Carve-Out. Upon completion of the ▇▇▇▇▇▇▇ Carve-Out, the ownership of Eleusis will be carved out to the existing shareholders of ▇▇▇▇▇▇▇ Psytech on a pro-rata basis consistent with the shareholders’ then outstanding issued share ownership of ▇▇▇▇▇▇▇ Psytech. See Note 3 below.

Replacement Awards and Consideration Shares

The Share Purchase Agreement contains provisions relating to the treatment of the holders of ▇▇▇▇▇▇▇ Options (the “▇▇▇▇▇▇▇ Optionholders”). Certain ▇▇▇▇▇▇▇ Optionholders that holds Vested and In-the-money ▇▇▇▇▇▇▇ Options at Closing shall, at atai’s sole discretion, either be given (i) Replacement Awards, (ii) Consideration Shares (with such number of Consideration Shares issued being adjusted to reflect the payment by atai of certain employment taxes arising on the cancellation of ▇▇▇▇▇▇▇ Options in exchange for Consideration Shares and the exercise price of such options), or (iii) a combination of the foregoing. ▇▇▇▇▇▇▇ Options held by any ▇▇▇▇▇▇▇ Optionholder who is a former employee or former contractor of ▇▇▇▇▇▇▇, or a non-natural person, shall lapse at Closing unless exercised (and the exercise price and related taxes paid) prior to Closing. Any issuance of (i) Consideration Shares or (ii) granting of the Replacement Awards to ▇▇▇▇▇▇▇ Optionholders shall reduce the aggregate number of 105,044,902 Consideration Shares to be issued to the Sellers upon the Closing. Since the Vested and In-the-money ▇▇▇▇▇▇▇ Options would be replaced with either Replacement Awards or Consideration Shares, this would lead to different outcomes regarding the total purchase consideration. To illustrate these potential outcomes, management discloses separate scenarios for the estimated purchase consideration in Note 7.

Consideration Shares and any Replacement Awards will be subject to a lock-up period whereby 1/12th of the Consideration Shares held by the Sellers following Closing shall be released from the lock-up each calendar month, resulting in all of the Consideration Shares then held by the Sellers being freely transferable on the 13th month following Closing.

8
Pre-Existing Investment in ▇▇▇▇▇▇▇ Psytech

In January 2024, atai and ▇▇▇▇▇▇▇ Psytech entered into (i) the SSA, pursuant to which atai acquired a total of 24,096,487 newly issued Series C Shares and (ii) a secondary sale purchase agreement (“Secondary Sale SPA”), pursuant to which atai acquired a total of 11,153,246 ordinary shares of ▇▇▇▇▇▇▇ Psytech, all of which were re-designated into Series C Shares. Additionally, in connection with the SSA, atai executed a deferred payment escrow agreement (the “Escrow Agreement”), deposited $15.0 million into an escrow account in exchange for a corresponding number of Series C Shares, and recognized a contingent forward liability of $2.9 million within Other current liabilities in its historical consolidated balance sheet related to the fair value of 9,036,144 Series C Shares (the “Deferred Shares”). Under the terms of the Escrow Agreement, ▇▇▇▇▇▇▇ Psytech could initially draw down up to $5.0 million from the escrow account, with the remaining balance to be drawn on April 1, 2025. In October 2024, ▇▇▇▇▇▇▇ Psytech drew down $5.0 million from the escrow account and the associated contingent forward liability of $1.0 million was derecognized. Subsequently, in April 2025, ▇▇▇▇▇▇▇ Psytech drew down $10.0 million from the escrow account and the associated contingent forward liability of $1.9 million was derecognized. As of June 30, 2025, atai had a total pre-existing investment in ▇▇▇▇▇▇▇ Psytech of 33.7%. The investment in ▇▇▇▇▇▇▇ Psytech Series C Shares is accounted for in accordance with the alternative measurement under Accounting Standards Codification (“ASC”) 321, Investments–Equity Securities (“ASC 321”) and included in Other investments in atai’s historical consolidated balance sheet.

Additionally, in connection with the SSA, on January 3, 2024, atai entered into an agreement with ▇▇▇▇▇▇▇ Psytech (the “Initial Warrant Agreement”) pursuant to which it received warrants to purchase 24,096,385 Series C Shares (the “▇▇▇▇▇▇▇ Warrants”), which were accounted for under the alternative measurement in accordance with ASC 321 and included in Other investments in atai’s historical consolidated balance sheet.

Pursuant to the Initial Warrant Agreement, atai also received the right to additional warrants (the “Additional ▇▇▇▇▇▇▇ Warrants”) to purchase Series C Shares in the event ▇▇▇▇▇▇▇ Psytech issued equity or equity linked securities pursuant to a deferred equity arrangement in connection with ▇▇▇▇▇▇▇ Psytech’s prior acquisition of Eleusis. The Additional ▇▇▇▇▇▇▇ Warrants meet the definition of a derivative instrument under ASC 815, Derivatives and Hedging (“ASC 815”), and were included in Other investments held at fair value in atai’s historical consolidated balance sheet, with subsequent changes in fair value being reflected through atai’s historical consolidated statements of operations in the Change in fair value of assets and liabilities, net. In May 2024, ▇▇▇▇▇▇▇ Psytech issued equity pursuant to the deferred equity arrangement, and atai received 4,393,400 of Additional ▇▇▇▇▇▇▇ Warrants. As of June 30, 2025, atai had an aggregate 28,489,785 of ▇▇▇▇▇▇▇ Warrants in a carrying amount of $8.5 million. As of June 30, 2025, atai estimated zero value of the Additional ▇▇▇▇▇▇▇ Warrants, which are no longer expected to be issued considering certain provisions of the Share Purchase Agreement. As a result, atai recognized a loss of $2.8 million during the six months ended June 30, 2025.

Pursuant to the Initial Warrant Agreement, the ▇▇▇▇▇▇▇ Warrants and the Additional ▇▇▇▇▇▇▇ Warrants, to the extent unexercised, will automatically lapse and be cancelled in connection with the Acquisition. As of June 30, 2025, no ▇▇▇▇▇▇▇ Warrants or Additional ▇▇▇▇▇▇▇ Warrants have been exercised.

Break Fee

The Share Purchase Agreement contains certain termination rights in favor of atai in circumstances where (a) certain milestones are not met relating to ▇▇▇▇▇▇▇ Psytech’s Phase 2b clinical trial in respect of BPL-003 and the Board changes its recommendation to seek the Shareholder Approval (the “Changed Board Recommendation”), in which case, atai can terminate the Share Purchase Agreement and shall pay a break fee of $4.0 million to ▇▇▇▇▇▇▇ Psytech either in cash or through the issuance of shares in atai to ▇▇▇▇▇▇▇ Psytech, (b) the Shareholder Approval is not obtained by the Longstop Date, in which case atai shall pay a break fee equal to $10.0 million to ▇▇▇▇▇▇▇ Psytech to be settled either in cash or through the issue of shares in atai (or a combination of both) to ▇▇▇▇▇▇▇ Psytech or (c) the Warranty Condition is not satisfied. The Ordinary Shares to be issued will be calculated based on the 20-day volume-weighted average price per share (the “VWAP”) as at the date falling ten days after (a) the date of the Changed Board Recommendation or (b) the Longstop Date. Any party to the Share Purchase Agreement may terminate the Share Purchase Agreement if the Shareholder Approval is not received by the Longstop Date.

For the purposes of this clause, the fee would be paid by atai is referred to as “Break Fee” and the Ordinary Shares that would be issued are referred to as “Break Fee Shares”. The unaudited pro forma condensed combined financial information does not reflect the potential payment related to the Break Fee or Break Fee Shares, as such payments are considered remote and not probable at the time of filing this Exhibit 99.2 .

9
On July 1, 2025, the milestones referenced above in respect of BPL-003 were met as atai and ▇▇▇▇▇▇▇ Psytech announced positive topline results from the Phase 2b clinical trial.

Closing Conditions

The Closing is subject to the satisfaction of closing conditions, including (i) the approval by atai shareholders of resolutions of atai’s general meeting by the date falling six months following the date of the Share Purchase Agreement, subject to up to two automatic extensions of 90 days in certain circumstances as described in the Share Purchase Agreement and the side letter entered into on August 13, 2025 (as so extended, the “Longstop Date”) to (x) approve the Acquisition (including the issuance of the Consideration Shares to the Sellers), (y) appoint certain director nominees to the Board and (z) change atai’s name to ▇▇▇▇ ▇▇▇▇▇▇▇ N.V., and (ii) the warrantors bringing down certain warranties in the Share Purchase Agreement at Closing, subject to a carve-out for any inaccuracies that would not have a material adverse effect in excess of £25.0 million, other than inaccuracies that relate to clinical validity matters relating to the Phase 2b clinical trial of BPL-003, on the ▇▇▇▇▇▇▇ Group.

Registration Rights Agreement

In connection with the Acquisition, the Sellers who will receive Consideration Shares in the Acquisition and that will sign joinders at Closing, will become parties to the Registration Rights Agreement (the “Registration Rights Agreement”), to become effective upon the Closing. Pursuant to the Registration Rights Agreement, atai is required to file a registration statement to register the Consideration Shares within 30 calendar days following the earlier of (i) the closing of the transactions contemplated by the Share Purchase Agreement and (ii) the termination of the Share Purchase Agreement. See “Registration Rights Agreement” under the section “Certain Relationships and Related Party Transactions” for further details.

Promissory Note

On August 13, 2025, atai and ▇▇▇▇▇▇▇ Psytech entered into the Promissory Note, pursuant to which atai will advance an aggregate principal amount of up to $10.0 million to ▇▇▇▇▇▇▇ Psytech to be used for the achievement of certain development milestones of BPL-003. The Promissory Note bears interest at a rate equal to the lesser of 12% per annum and the highest rate permitted by applicable law. The outstanding principal balance of the Promissory Note and all accrued but unpaid interest are due and payable in full on the earlier of (i) the payment of the Break Fee, (ii) three hundred sixty-four days from the date of the first advance, and (iii) the occurrence of an event of default pursuant to the Promissory Note. The Promissory Note and the related interest, if any, will be expected to be effectively settled since such a transaction becomes an intercompany transaction upon the Closing and will be eliminated in the postcombination financial statements of the Combined Group. Therefore, the settlement of the Promissory Note of $10.0 million will be included as part of the purchase consideration (see Note 7).

2. Historical ▇▇▇▇▇▇▇ Psytech

The historical consolidated financial statements of ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ as of and for the six months ended June 30, 2025 and as of and for the year ended December 31, 2024 were prepared in pound sterling (“GBP”), the presentational currency, and as of and for the year ended December 31, 2024 in accordance with IFRS accounting standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and as of and for the six months ended June 30, 2025 in accordance with International Accounting Standard 34 — Interim Financial Reporting as issued by the IASB. For purposes of preparing the unaudited pro forma condensed combined financial information, all amounts in ▇▇▇▇▇▇▇ Psytech’s historical consolidated statement of financial position as of June 30, 2025 were converted to U.S. Dollar (“USD”) using an exchange rate of 1.3737 USD per GBP at that date. All of ▇▇▇▇▇▇▇ Psytech’s historical consolidated statement of comprehensive loss amounts for the year ended December 31, 2024 were converted to USD using the average exchange rate for the year of 1.2778 USD per GBP. All of ▇▇▇▇▇▇▇ Psytech’s historical consolidated statement of comprehensive loss amounts for the six months ended June 30, 2025 were converted to USD using the average exchange rate for the period of 1.3070 USD per GBP.

10
The following tables reflect the conversion of the historical consolidated financial statements of ▇▇▇▇▇▇▇ Psytech to USD.

   
Interim Consolidated Statement of Financial Position
As of June 30, 2025
  
   
Historical
▇▇▇▇▇▇▇ Psytech
(IFRS)
    
USD
Conversion
Rate
    
Historical
▇▇▇▇▇▇▇ Psytech
(IFRS)
  
   
(GBP)
          
(USD)
  
Assets
                  
Non-Current assets
                  
Property, plant and equipment
  
£
75
      
1.3737
    
$
103
  
Intangible assets
    
48,478
      
1.3737
      
66,594
  
Other receivables
    
2,287
      
1.3737
      
3,142
  
Total Non-Current Assets
    
50,840
              
69,839
  
Current assets
                        
Other receivables
    
1,065
      
1.3737
      
1,463
  
Tax receivables
    
8,705
      
1.3737
      
11,958
  
Cash and cash equivalents
    
1,622
      
1.3737
      
2,228
  
Total current assets
    
11,392
              
15,649
  
Total assets
  
£
62,232
            
$
85,488
  
Liabilities and shareholders’ equity
                        
Liabilities
                        
Current liabilities
                        
Trade and other payables
  
£
3,608
      
1.3737
    
$
4,956
  
Contingent consideration
    
13,232
      
1.3737
      
18,177
  
Total Current liabilities
    
16,840
              
23,133
  
Non-Current Liabilities
                        
Contingent consideration
    
5,973
      
1.3737
      
8,205
  
Warrants
    
318
      
1.3737
      
437
  
Total Non-Current Liabilities
    
6,291
              
8,642
  
Total liabilities
    
23,131
              
31,775
  
Net assets
    
39,101
              
53,713
  
Issued capital and reserves
                        
Share capital
    
10
      
1.3737
      
14
  
Share premium
    
95,656
      
1.3737
      
131,402
  
Merger reserve
    
31,988
      
1.3737
      
43,942
  
Cumulative translation adjustment
    
(562
)
    
1.3737
      
(772
)
Accumulated deficit
    
(87,991
)
    
1.3737
      
(120,873
)
Total equity
  
£
39,101
            
$
53,713
  

11


   
Interim Condensed Consolidated Statement of Comprehensive Loss
For the six months ended June 30, 2025
  
   
Historical
▇▇▇▇▇▇▇ Psytech
(IFRS)
    
USD
Conversion
Rate
    
Historical
▇▇▇▇▇▇▇ Psytech
(IFRS)
  
   
(GBP)
          
(USD)
  
Operating expenses:
                  
General and administrative
  
£
(5,219
)
    
1.3070
    
$
(6,821
)
Research and development
    
(11,406
)
    
1.3070
      
(14,907
)
Loss on contingent consideration
    
(14,121
)
    
1.3070
      
(18,456
)
Operating loss
    
(30,746
)
            
(40,184
)
Interest income
    
76
      
1.3070
      
99
  
Interest expense
    
(84
)
    
1.3070
      
(110
)
Gain on revaluation of warrants
    
6,765
      
1.3070
      
8,842
  
Other non-operating income
    
6,757
              
8,831
  
Loss before income taxes
    
(23,989
)
            
(31,353
)
Income tax benefit
    
3,896
      
1.3070
      
5,093
  
Loss for the period
  
£
(20,093
)
          
$
(26,260
)

   
Consolidated Statement of Comprehensive Loss
For the year ended December 31, 2024
  
   
Historical
▇▇▇▇▇▇▇ Psytech
(IFRS)
    
USD
Conversion
Rate
    
Historical
▇▇▇▇▇▇▇ Psytech
(IFRS)
  
   
(GBP)
          
(USD)
  
Operating expenses:
                  
General and administrative
  
£
(7,984
)
    
1.2778
    
$
(10,202
)
Research and development
    
(24,445
)
    
1.2778
      
(31,237
)
Loss on contingent consideration
    
(3,494
)
    
1.2778
      
(4,465
)
Operating loss
    
(35,923
)
            
(45,904
)
Interest income
    
929
      
1.2778
      
1,187
  
Gain on revaluation of warrants
    
4,141
      
1.2778
      
5,291
  
Loss before income taxes
    
(30,853
)
            
(39,426
)
Income tax benefit
    
8,384
      
1.2778
      
10,713
  
Loss for the year
  
£
(22,469
)
          
$
(28,713
)

3. Adjusted ▇▇▇▇▇▇▇ Psytech

In the unaudited pro forma condensed combined financial information, Adjusted ▇▇▇▇▇▇▇ Psytech is the historical consolidated financial statements of ▇▇▇▇▇▇▇ Psytech after giving effect to the ▇▇▇▇▇▇▇ Carve-Out. The ▇▇▇▇▇▇▇ Carve-Out reflected in the unaudited pro forma condensed combined financial information has been prepared on a “carve-out” basis of accounting. As both atai and the Sellers shall make all reasonable endeavors to effect the ▇▇▇▇▇▇▇ Carve-Out in alignment with the ▇▇▇▇▇▇▇ Carve-Out Steps Plan, and the Acquisition is expected to be consummated subsequent to the completion of the ▇▇▇▇▇▇▇ Carve-Out, management has assessed the ▇▇▇▇▇▇▇ Carve-Out as probable of occurring prior to the Closing. Upon completion of the ▇▇▇▇▇▇▇ Carve-Out, Eleusis will be carved out from ▇▇▇▇▇▇▇ Psytech by way of a dividend in specie of all of the issued shares in Eleusis such that the shareholders of ▇▇▇▇▇▇▇ Psytech immediately prior to the ▇▇▇▇▇▇▇ Carve-Out shall each receive a pro-rata equity holding in Eleusis. As of June 30, 2025, atai held a 33.7% investment in ▇▇▇▇▇▇▇ Psytech. As a result, atai will hold a 33.7% interest in Eleusis, which is recognized at its estimated fair value of $1.8 million in the unaudited pro forma condensed combined financial information.

12
There has been no allocation for business and support functions, such as expenses for research and development and corporate administrative services, including information technology, finance, legal, insurance, compliance and human resources activities, from ▇▇▇▇▇▇▇ Psytech to Eleusis as these expenses are considered immaterial to the operations of the Combined Group for the periods presented in the unaudited pro forma condensed combined financial information.

The adjustments included in the unaudited pro forma condensed combined financial information related to the ▇▇▇▇▇▇▇ Carve-Out described above are as follows:


 a)
Represents the carrying value of the assets and liabilities of Eleusis as of June 30, 2025 and a corresponding equity contribution of $71.2 million within share premium.


b)
Represents the results of operations of Eleusis for the six months ended June 30, 2025 and the year ended December 31, 2024.

Upon completion of the ▇▇▇▇▇▇▇ Carve-Out, the historical financial results of Eleusis may be reflected in ▇▇▇▇▇▇▇ Psytech’s consolidated financial statements as discontinued operations under IFRS. The transaction accounting adjustments represent the best estimates based on information currently available and may differ from those that may be calculated to report Eleusis as discontinued operations in ▇▇▇▇▇▇▇ Psytech’s consolidated financial statements in future filings.

4. July PIPE Financing

On July 1, 2025, atai entered into the July PIPE Financing (see Introduction to the unaudited condensed combined pro forma financial information). The adjustments included in the unaudited pro forma condensed combined balance sheet related to the July PIPE Financing described above are as follows:


 a)
To reflect the aggregate issuance and sale of 18,264,840 Ordinary Shares and the July Pre-Funded Warrants to purchase 4,566,210 Ordinary Shares to the PIPE investors pursuant to subscription agreements, for aggregate net proceeds of $46.7 million. The proceeds of the July PIPE Financing were recorded net of preliminary estimated transaction costs of approximately $3.3 million, of which $0.7 million was allocated to the July Pre-Funded Warrants. The July Pre-Funded Warrants are determined to be liability-classified. The issuance of Ordinary Shares in connection with the July PIPE Financing is recorded at the par value of €0.10 (USD $0.12 at June 30, 2025) per share of $2.1 million, with the remaining net proceeds of $35.2 million recorded in additional paid-in capital. The issuance of the July Pre-Funded Warrants is recorded as a warrant liability of $10.0 million, which will be remeasured to fair value at each subsequent reporting period based on the stock price of atai less the exercise price of the July Pre-Funded Warrants, and associated estimated transaction costs are reflected as an increase in accumulated deficit of $0.7 million.


b)
To reflect the transaction costs of $0.7 million allocated to the July Pre-Funded Warrants as an increase to general and administrative expenses, assuming that the adjustment described in Note 4(a) was made on January 1, 2024.

5. Basis of Pro Forma Presentation

The unaudited pro forma condensed combined financial information has been prepared by management in accordance with Article 11, and is presented in USD. The adjustments presented in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an understanding of the Combined Group after the consummation of the Acquisition, the July PIPE Financing, the ▇▇▇▇▇▇▇ Carve-Out, the Redomiciliation, and other related transactions.

The unaudited pro forma condensed combined financial information reflects certain adjustments to convert Adjusted ▇▇▇▇▇▇▇ Psytech’s consolidated financial information derived from the historical consolidated financial statements of ▇▇▇▇▇▇▇ Psytech under IFRS to GAAP and to align the financial information with atai’s accounting policies (see Note 8(e)). These adjustments reflect atai’s best estimates based on the information currently available.

The unaudited pro forma condensed combined balance sheet as of June 30, 2025 reflects adjustments that depict the accounting for the Acquisition using the acquisition method of accounting under GAAP, the July PIPE Financing, the ▇▇▇▇▇▇▇ Carve-Out, the Redomiciliation, and other related other transactions. The unaudited pro forma condensed combined statements of operations for the year ended December 31, 2024 and for the six months ended June 30, 2025 each reflect adjustments that give effect to atai’s results of operations as if those adjustments for the Acquisition, the July PIPE Financing, the ▇▇▇▇▇▇▇ Carve-Out, the Redomiciliation, and other related transactions were made on January 1, 2024, the first day of the earliest period presented.

13
The unaudited pro forma condensed combined financial information does not give effect to any anticipated synergies, operating efficiencies, tax savings, or cost savings that may be associated with the Acquisition and other related transactions. In addition, the income tax effects of the transaction accounting adjustments are not expected to be meaningful given the combined entity incurred significant losses during the historical periods presented , and therefore, no income tax adjustments are included in the unaudited pro forma condensed combined financial information. The unaudited pro forma condensed combined financial information constitutes forward-looking information, is subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated and should be read in conjunction with the accompanying notes thereto.

The transaction accounting adjustments are preliminary and are based upon available information and certain assumptions which management believes are reasonable under the circumstances and which are described in the accompanying notes to the unaudited pro forma condensed combined financial information. Actual results may differ materially from the assumptions within the accompanying unaudited pro forma condensed combined financial information. The final purchase price allocation will be determined when the final purchase consideration has been determined, detailed valuations and any other studies and calculations deemed necessary have been completed. Therefore, the actual amounts recorded as of the completion of the Acquisition may also differ materially from the information presented in this unaudited condensed combined pro forma information as a result of, among other factors, changes in the fair value of atai’s Common Stock, the timing of Closing, and changes in ▇▇▇▇▇▇▇ Psytech’s assets and liabilities that occur prior to the Closing.

6. Accounting Treatment for the Acquisition

The Acquisition is expected to be accounted for using the asset acquisition method in accordance with GAAP because substantially all of the fair value is concentrated in an in process research and development (“IPR&D”) asset, an intangible asset. Under this method of accounting, no goodwill will be recognized. In addition, upon Closing, the equity at risk for ▇▇▇▇▇▇▇ Psytech is not considered sufficient for ▇▇▇▇▇▇▇ Psytech to finance its activities without additional subordinated financial support. As a result, ▇▇▇▇▇▇▇ Psytech will be considered a variable interest entity (“VIE”) at the Closing, and the primary beneficiary of ▇▇▇▇▇▇▇ Psytech will be treated as the accounting acquirer. Upon the consummation of the Acquisition, atai will own 100% of ▇▇▇▇▇▇▇ Psytech and will retain the obligation to absorb the losses and/or receive the benefits of ▇▇▇▇▇▇▇ Psytech that could potentially be significant to ▇▇▇▇▇▇▇ Psytech. As such, atai will be considered the primary beneficiary of ▇▇▇▇▇▇▇ Psytech upon the Closing and therefore, the accounting acquirer.

Cash, working capital and other nominal assets and liabilities of ▇▇▇▇▇▇▇ Psytech will be accounted for at their fair values. The remaining fair value of consideration transferred will be allocated to the IPR&D, based on the fair value as determined by a third-party valuation specialist. Since there will be no goodwill recognized, a gain or loss will be recorded for the difference between the carrying amount of atai’s previously held interest in Series C Shares and the ▇▇▇▇▇▇▇ Warrants, the outstanding principal balance and all accrued but unpaid interest of the Promissory Note, and the net amount of Adjusted ▇▇▇▇▇▇▇ Psytech’s identifiable assets and liabilities recognized and measured.

14
7. Preliminary Estimated Purchase Consideration

Pursuant to the Share Purchase Agreement, the entire issued share capital of ▇▇▇▇▇▇▇ Psytech, other than the shares already held by atai, will be exchanged for 105,044,902 Consideration Shares at Closing. At atai’s sole discretion, atai could issue Replacement Awards in the form of its stock options or restricted stock units or Consideration Shares, for all Vested and In-the-money ▇▇▇▇▇▇▇ Options at Closing. Any issuance of Consideration Shares or granting of the Replacement Awards to ▇▇▇▇▇▇▇ Optionholders shall reduce the aggregate number of 105,044,902 Consideration Shares to be issued to the Sellers upon the Acquisition. atai has assumed replacing all Vested and In-the-money ▇▇▇▇▇▇▇ Options in the form of its restricted stock units, subject to the aforementioned lock-up provisions, to be the most likely scenario (the “RSU Consideration Scenario”) at Closing (see Note 1, Replacement Awards and Consideration Shares). The RSU Consideration Scenario is therefore assumed for purposes of this pro forma presentation; however, atai is under no obligation to effectuate the RSU Consideration Scenario, and there can be no guarantee that it will effectuate the RSU Consideration Scenario or that the RSU Consideration Scenario will represent the ultimate mix of consideration to be issued in the Acquisition, which would have an impact on the pro forma presentation herein. Under this RSU Consideration Scenario, the ▇▇▇▇▇▇▇ Optionholders will be entitled to receive 13,744,099 of the total 105,044,902 Consideration Shares, representing the total outstanding Vested and In-the-money ▇▇▇▇▇▇▇ Options at the date of this Exhibit 99.2 after applying the preliminary estimated exchange ratio of 1.3130 pursuant to the Share Purchase Agreement, as Replacement Awards at Closing in the form of atai restricted stock units. The ▇▇▇▇▇▇▇ Optionholders will receive such atai restricted stock units net of the exercise price of the respective Vested and In-the-money ▇▇▇▇▇▇▇ Options and as a result, 10,199,886 atai restricted stock units are assumed to be issued by atai. The following table based on the RSU Consideration Scenario summarizes the estimated preliminary purchase consideration of approximately $523.2 million upon the Closing (in thousands, except shares and per share amounts):

atai Ordinary Shares and atai restricted stock units issued for consideration at Closing(1)
    
101,500,689
  
Closing trading price(2)
  

4.52
  
Share consideration issued to the Sellers
  

458,783
  
Settlement of the Promissory Note (see Note 1)
    
10,000
  
Reported value of atai’s previously held interest in ▇▇▇▇▇▇▇ Psytech (see Note 8(g))
    
53,947
  
Estimated fair value of the assumed ▇▇▇▇▇▇▇ Options at Closing (see Note 8(g))
    
518
  
Total preliminary estimated purchase consideration
  

523,248
  
(1)
A sum of 91,300,803 atai Ordinary Shares and 10,199,886 atai restricted stock units are assumed to be issued at Closing based on the RSU Consideration Scenario.

(2)
The preliminary estimated purchase consideration is based on the closing trading price of atai Ordinary Shares on Nasdaq on September 3, 2025.

15
The estimated purchase consideration of the RSU Consideration Scenario in the unaudited pro forma condensed combined financial information was calculated in accordance with the terms of the Share Purchase Agreement using information available as of the date of this Exhibit 99.2 . The final purchase price could significantly differ from the amounts presented in the unaudited pro forma condensed combined financial information due to, among other factors, movements in Ordinary Shares price up to the Closing. A sensitivity analysis related to the fluctuation in the closing trading price of atai Ordinary Shares of $4.52 was performed to assess the impact a hypothetical change of 10% in the closing trading price, would have on the preliminary estimated purchase consideration as of the Closing. The following table shows the change in the closing trading price of Ordinary Shares and resulting preliminary estimated purchase price (in thousands, except shares and per share amounts):

     
+10%

   
-10%

atai Ordinary Shares and atai restricted stock units issued for consideration at Closing(1)
    
101,500,689
      
101,500,689
  
Closing share price with a hypothetical change of 10%
  

4.97
    

4.07
  
Share consideration issued to the Sellers
  

504,661
    

412,905
  
Settlement of the Promissory Note (see Note 1)
    
10,000
      
10,000
  
Reported value of atai’s previously held interest in ▇▇▇▇▇▇▇ Psytech (see Note 8(g))
    
53,947
      
53,947
  
Estimated fair value of the assumed ▇▇▇▇▇▇▇ Options at Closing (see Note 8(g))
    
518
      
518
  
Total preliminary estimated purchase consideration
  

569,126
    

477,370
  
(1)
A sum of 91,300,803 atai Ordinary Shares and 10,199,886 atai restricted stock units are assumed to be issued at Closing based on the RSU Consideration Scenario.

If atai elects to issue atai stock options or Consideration Shares in exchange for all Vested and In-the-money ▇▇▇▇▇▇▇ Options, then the estimated preliminary purchase consideration upon the Closing is determined as follows, respectively (in thousands, except shares and per share amounts):

   
All Vested and
In-the-money ▇▇▇▇▇▇▇
Options Replaced by
atai Stock Options
    
All Vested and
In-the-money ▇▇▇▇▇▇▇
Options Exchanged
for Consideration
Shares
  
atai Ordinary Shares issued for consideration at Closing
    
91,300,803
 
    
97,420,721
 
Closing trading price(3)
  

4.52
    

4.52
  
Share consideration issued to the Sellers
  

412,680
    

440,342
  
Settlement of the Promissory Note (see Note 1)
    
10,000
      
10,000
  
Reported value of atai’s previously held interest in ▇▇▇▇▇▇▇ Psytech (see Note 8(g))
    
53,947
      
53,947
  
Estimated employment taxes on the cancellation of the Vested and In-the-money ▇▇▇▇▇▇▇ Options in exchange for the Consideration Shares(4)
    
—
      
16,809
  
Estimated fair value of the assumed ▇▇▇▇▇▇▇ Options at Closing (see Note 8(g))
    
51,184
      
518
  
Total preliminary estimated purchase consideration
  

527,811
    

521,616
  
(1)
If atai elects to issue atai stock options in exchange for all Vested and In-the-money ▇▇▇▇▇▇▇ Options, the Sellers will be expected to receive 91,300,803 atai Ordinary shares and the ▇▇▇▇▇▇▇ Optionholders will be expected to receive 13,744,099 atai stock options as Replacement Awards at Closing.

(2)
If atai elects to issue Consideration Shares in exchange for all Vested and In-the-money ▇▇▇▇▇▇▇ Options, the ▇▇▇▇▇▇▇ Optionholders will be entitled to receive 13,744,099 of the total 105,044,902 Consideration Shares at Closing. The ▇▇▇▇▇▇▇ Optionholders will receive such Consideration Shares net of the ▇▇▇▇▇▇▇ Optionholders’ cost to exercise such ▇▇▇▇▇▇▇ Options and the related tax liability and as a result, 6,119,918 Consideration Shares will be expected to be issued by atai. As a result, a total of 97,420,721 atai Ordinary Shares will be issued at Closing.

(3)
The preliminary estimated purchase consideration is based on the closing trading price of atai Ordinary Shares on Nasdaq on September 3, 2025.

(4)
If atai elects to issue Consideration shares in exchange for all Vested and In-the-money ▇▇▇▇▇▇▇ Options, atai is obligated to pay the related estimated tax liability in respect of each ▇▇▇▇▇▇▇ Optionholders cancelled options to the relevant tax authority, pursuant to the Share Purchase Agreement.


16
8. Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet

The adjustments and notes included in the unaudited pro forma condensed combined balance sheet as of June 30, 2025, based on preliminary estimates that could change materially as additional information is obtained, are as follows:

Balance Sheet Pro forma Transaction Accounting Adjustments:

atai pro forma transaction accounting adjustments:


 a)
To reflect the exercise of 2,987,065 atai stock options for net proceeds of $4.5 million subsequent to June 30, 2025.


b)
To reflect the transfer of funds to ▇▇▇▇▇▇▇ Psytech in connection with the issuance of the Promissory Note subsequent to June 30, 2025 as a decrease in cash and cash equivalents of $10.0 million and a corresponding increase in note receivable from ▇▇▇▇▇▇▇ Psytech (see Note 1, Promissory Note).


c)
To reflect preliminary estimated transaction costs of $8.2 million, not yet reflected in the historical consolidated financial statements of atai, which are expected to be incurred by atai in connection with the Acquisition, such as advisory, legal, regulatory and auditor fees, as a decrease in accounts payable of $0.2 million, a decrease in accrued liabilities of $3.2 million, a decrease in cash of $11.6 million, reflecting $3.4 million of estimated transaction costs accrued as of June 30, 2025 and $8.2 million of estimated transactions costs not yet reflected in the historical consolidated financial statements of atai, and an increase in accumulated deficit of $8.2 million. Transaction costs incurred by atai are not considered part of the fair value of the identifiable assets and liabilities of the acquired VIE in an asset acquisition and, therefore, are expensed as incurred.

Adjusted ▇▇▇▇▇▇▇ Psytech pro forma transaction accounting adjustments:


 d)
To reflect the receipt of proceeds from atai in connection with the Promissory Note issued subsequent to June 30, 2025, as an increase of $10.0 million in cash and cash equivalents and note payable to atai (see Note 1, Promissory Note).


e)
To reflect the adjustments to convert Adjusted ▇▇▇▇▇▇▇ Psytech’s consolidated financial information from IFRS to GAAP. These adjustments reflect management’s best estimates based upon the information available. The following adjustments have been made to align Adjusted ▇▇▇▇▇▇▇ Psytech’s IFRS consolidated financial information with a basis consistent with GAAP:


1.
Under IFRS, ▇▇▇▇▇▇▇ Psytech historically recognized share-based compensation costs for share-based awards with graded-vesting schedules over the requisite service period for each separately vesting portion of the award. Adjustment 8(e.1) reflects the adjustment to recognize the total share-based compensation cost for such share-based awards on a straight-line basis over the requisite service period in accordance with atai’s accounting policy under GAAP. This resulted in a decrease in the additional paid-in capital of $1.7 million and a corresponding decrease in accumulated deficit.


2.
As part of the preparation of the unaudited pro forma condensed combined financial information:


○
$1.2 million of prepayments reflected in Adjusted ▇▇▇▇▇▇▇ Psytech’s other receivables derived from the historical consolidated financial statements of ▇▇▇▇▇▇▇ Psytech were reclassified to prepaid expenses and other current assets to align with the presentation of atai’s historical consolidated financial information;


○
$2.5 million of current liabilities reflected in Adjusted ▇▇▇▇▇▇▇ Psytech’s trade and other payables derived from the historical consolidated financial statements of ▇▇▇▇▇▇▇ Psytech were reclassified to accounts payable to align with the presentation of atai’s historical consolidated financial information; and


○
$2.4 million of accruals reflected in Adjusted ▇▇▇▇▇▇▇ Psytech’s trade and other payables derived from the historical consolidated financial statements of ▇▇▇▇▇▇▇ Psytech were reclassified to accrued liabilities to align with the presentation of atai’s historical consolidated financial information.

17

 f)
To reflect the settlement of the warrant liability of $0.4 million recognized in Adjusted ▇▇▇▇▇▇▇ Psytech’s consolidated financial information related to the ▇▇▇▇▇▇▇ Warrants and the Additional ▇▇▇▇▇▇▇ Warrants as the warrants will be cancelled upon consummation of the Acquisition, pursuant to the Initial Warrant Agreement (see Note 1, Pre-Existing Investment in ▇▇▇▇▇▇▇ Psytech). This adjustment is reflected as a decrease in the warrant liability of $0.4 million and a corresponding decrease in accumulated deficit.

Acquisition accounting adjustments:


 g)
To reflect the asset acquisition and the resulting elimination of the equity of Adjusted ▇▇▇▇▇▇▇ Psytech, based on the RSU Consideration Scenario, as summarized below (in thousands):


Share Consideration issued to the Sellers(1)
  
$
458,783
  
Settlement of the Promissory Note(2)
    
10,000
  
Reported value of atai’s previously held interest in ▇▇▇▇▇▇▇ Psytech(3)
    
53,947
  
Estimated fair value of the assumed ▇▇▇▇▇▇▇ Options at Closing(4)
    
518
  
Total preliminary estimated purchase consideration
  
$
523,248
  
Cash and cash equivalents
    
12,170
  
Tax receivables
    
10,046
  
Prepaid expenses and other current assets
    
1,231
  
Estimated fair value of the investment in Eleusis
    
1,800
  
Estimated fair value in-process research and development
    
536,000
  
Accounts payable
    
(2,517
)
Accrued liabilities
    
(2,355
)
Current and noncurrent portion of contingent consideration
    
(26,382
)
Total net assets acquired
    
529,993
  
Gain on the Acquisition
  
$
(6,745
)
(1)
Represents the aggregate fair value of 91,300,803 newly issued, unregistered shares of atai Ordinary Shares and 10,199,886 atai restricted stock units (subject to the aforementioned lock-up provisions) to be issued to the Sellers as consideration for the Acquisition of $458.8 million based on the RSU Consideration Scenario. The fair value was measured using a closing trading price of atai Ordinary Shares of $4.52 on September 3, 2025, and is subject to fluctuation as the share price of atai Ordinary Shares changes through the date of the Closing (see Note 6).

(2)
Represents the settlement of the Promissory Note issued from ▇▇▇▇▇▇▇ Psytech to atai on August 13, 2025 (see Note 1, Promissory Note).

(3)
Represents the carrying value of atai’s previously held equity interests in ▇▇▇▇▇▇▇ Psytech, including the carrying value of atai’s pre-existing investment in Series C Shares of $45.4 million and the carrying value of the outstanding ▇▇▇▇▇▇▇ Warrants of $8.5 million (see Note 1, Pre-Existing Investment in ▇▇▇▇▇▇▇ Psytech).

(4)
Represents the estimated acquisition-date fair value of the assumed underwater ▇▇▇▇▇▇▇ Options which are expected to be fully vested at the time of Closing. The fair value is determined based on the closing trading price of atai Ordinary Shares on September 3, 2025, the estimated expected term of the awards, and the estimated number of replacement awards to be issued to the holders of such underwater ▇▇▇▇▇▇▇ Options at Closing after applying the preliminary estimated exchange ratio of 1.3130 (see Note 1, Description of the Acquisition).

In accordance with ASC 810, atai, being primary beneficiary of ▇▇▇▇▇▇▇ Psytech, a VIE that is not a business, will recognize a gain/loss upon consummation of the Acquisition, representing the difference between (i) the sum of the consideration transferred for the Acquisition, the carrying value of atai’s previously held equity investment in ▇▇▇▇▇▇▇ Psytech, and the outstanding principal balance and all accrued but unpaid interest of the Promissory Note, and (ii) the fair value of Adjusted ▇▇▇▇▇▇▇ Psytech’s identifiable assets and liabilities at Closing, including the preliminary estimates of fair value of the acquired IPR&D and atai’s investment in Eleusis.

The fair value of the remaining net assets of Adjusted ▇▇▇▇▇▇▇ Psytech is expected to approximate their carrying values at the time of Closing. The fair value of acquired IPR&D is determined primarily using the income approach, which requires a forecast of all of the expected future cash flows with the following assumptions: net revenue attributable to the IPR&D, operating expenses, and contributory asset charges resulting from applying a terminal growth rate at the end of the discrete period. An estimated discount rate of 16.3% is applied to the projected cash flows of the IPR&D based on the rate of return used by a similar market participant. The preliminary estimate of fair value of acquired IPR&D will likely differ from final amount the Combined Group will calculate after completing a detailed valuation analysis, and the difference could have a material effect on the accompanying unaudited pro forma condensed combined financial information.
18


 h)
To reflect the derecognition of the acquired IPR&D, an intangible asset, with no alternative future use upon consummation of the Acquisition. This adjustment is reflected as a decrease in intangible asset of $536.0 million and a corresponding increase in accumulated deficit.


i)
To reflect preliminary estimated transaction costs of $2.3 million, not yet reflected in the historical consolidated financial statements of atai, which are expected to be incurred by atai in connection with the Redomiciliation, such as advisory, legal and auditor fees, as an increase in accrued liabilities and a corresponding increase in accumulated deficit (see Introduction to the unaudited condensed combined pro forma financial information).

9. Adjustments to Unaudited Pro Forma Condensed Combined Statements of Operations

The adjustments included in the unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2025 and for the year ended December 31, 2024, are as follows:

Pro forma notes:

Given that atai has reported net losses and applied a full valuation allowance for the reporting periods presented in the unaudited pro forma condensed consolidated financial information, management assumed an effective income tax rate of 0%. There have not been any identified changes to the income tax positions due to the Acquisition that would result in an incremental tax expense or benefit. Accordingly, no tax-related adjustments have been reflected in the pro forma condensed combined financial information.

Pro forma Transaction Accounting Adjustments:


 a)
To eliminate the change in fair value of the Additional ▇▇▇▇▇▇▇ Warrants recorded in the historical consolidated financial statements of atai, assuming that the warrants will be settled pursuant to the Initial Warrant Agreement as if the adjustment reflecting the accounting for the Acquisition was made on January 1, 2024.


b)
To eliminate the gain on revaluation of Adjusted ▇▇▇▇▇▇▇ Psytech’s warrant liability derived from the historical consolidated financial statements of ▇▇▇▇▇▇▇ Psytech, assuming that the warrants will be settled pursuant to the Initial Warrant Agreement as if the adjustment reflecting the accounting for the Acquisition was made on January 1, 2024.


c)
To reflect atai’s estimated advisory, legal, audit and other costs related to the Acquisition that are not recorded in its historical consolidated financial statements as an increase to general and administrative expenses, assuming that the adjustment described in Note 8(c) was made on January 1, 2024.


d)
To reflect the conversion of Adjusted ▇▇▇▇▇▇▇ Psytech’s stock-based compensation expense derived from the historical consolidated financial statements of ▇▇▇▇▇▇▇ Psytech from IFRS to GAAP, as described in Note 8(e.1).


e)
To reflect the gain on the Acquisition as described in Note 8(g).


f)
To reflect the derecognition of the acquired IPR&D in the Acquisition, as described in Note 8(h).


g)
To reflect atai’s estimated advisory, legal, audit and other costs related to the Redomiciliation that are not recorded in its historical consolidated financial statements as an increase to general and administrative expenses, assuming that the adjustment described in Note 8(i) was made on January 1, 2024.


h)
The pro forma combined basic and diluted net loss per share has been adjusted to reflect the Acquisition and related transactions, including the issuance of atai’s Ordinary Shares and the July Pre-Funded Warrants in connection with the July PIPE Financing, based on the RSU Consideration Scenario, as if such transactions had occurred on January 1, 2024. For periods in which atai, ▇▇▇▇▇▇▇ Psytech, or the Combined Group reported a net loss, diluted loss per share is the same as basic loss per share, since dilutive potential shares are not assumed to have been issued as their effect would be anti-dilutive.
19


   
For the Six
Months Ended
June 30, 2025
    
For the Year Ended
December 31, 2024
  
   
Basic and Diluted
    
Basic and Diluted
  
   
(in thousands, except shares and per share amounts)
  
Pro forma net loss
  
$
(85,625
)
  
$
( 721,186
)
Weighted average ordinary shares outstanding
    
186,473,494
      
160,159,983
  
Exercise of atai stock options subsequent to June 30, 2025
    
2,987,065
      
2,987,065
  
atai Ordinary Shares issued to the Sellers for consideration
    
101,500,689
      
101,500,689
  
atai Ordinary Shares issued in connection with the July PIPE Financing
    
18,264,840
      
18,264,840
  
Pro forma weighted average number of ordinary shares
    
309,226,088
      
282,912,577
  
Pro form net loss per share
  
$
(0.28
)
  
$
( 2.55
)

Assuming atai elects to issue atai stock options in exchange for all Vested and In-the-money ▇▇▇▇▇▇▇ Options, the pro forma weighted average number of ordinary shares as of June 30, 2025 and December 31, 2024 would be 299,026,203 and 272,712,691, respectively, and the pro forma net loss and pro forma combined basic and diluted net loss per share would be $0.1 million and $0.29 for the six months ended June 30, 2025, respectively, and $0.7 million and $ 2.66 for the year ended December 31, 2024, respectively.

Assuming atai elects to issue Consideration Shares in exchange for all Vested and In-the-money ▇▇▇▇▇▇▇ Options, the pro forma weighted average number of ordinary shares as of June 30, 2025 and December 31, 2024 would be 305,146,120 and 278,832,609, respectively, and the pro forma net loss and pro forma combined basic and diluted net loss per share would be $0.1 million and $0.28 for the six months ended June 30, 2025, respectively, and $0.7 million and $ 2.58 for the year ended December 31, 2024, respectively.

The following table reflects the outstanding dilutive potential shares that are excluded from the calculation of diluted net loss per share due to their anti-dilutive effect based on the RSU Consideration Scenario.

   
For the Six
Months Ended
June 30, 2025
    
For the Year Ended
December 31, 2024
  
atai unvested restricted stock units
    
—
      
719,557
  
atai options to purchase atai Ordinary Shares
    
48,565,515
      
40,042,921
  
atai HSOP options to purchase atai Ordinary Shares
    
6,921,829
      
6,921,829
  
atai 2018 short-term convertible promissory notes - related parties
    
2,367,200
      
2,367,200
  
atai 2018 short-term convertible promissory notes
    
3,818,704
      
3,818,704
  
July Pre-Funded Warrants issued in connection with the July PIPE Financing
    
10,877,216
      
10,877,216
  
Assumed ▇▇▇▇▇▇▇ Options to be issued to ▇▇▇▇▇▇▇ Optionholders in connection with the Acquisition
    
196,951
      
196,951
  
     
72,747,415
      
64,944,378
  


20

Document Metadata

Filed: September 29th, 2025